What Happens After Isotretinoin? New Insights Into Post-Treatment Acne Care Isotretinoin remains the gold standard for treating severe acne, but relapse after treatment is common, affecting 20 to 60% of…
Read More
The Hidden Role of C. acnes in Dandruff: Beyond the Flakes Dandruff affects nearly 50% of the global population, yet its exact causes remain under ongoing investigation. While most clinicians…
Read More
Isotretinoin Dosing in Adolescents: Does Weight Change Matter? Isotretinoin remains the gold standard for treating severe nodulocystic acne, with cumulative dosing of 120-150 mg/kg shown to balance safety and efficacy. Higher…
Read More
Upadacitinib may provide additional health benefits, including reducing the risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). That’s according to a May Journal of Drugs in Dermatology…
Read More
Faster Relief for Seborrheic Dermatitis? A Case for Topical Roflumilast Seborrheic dermatitis is a chronic inflammatory skin condition that often frustrates patients and clinicians alike, especially during flare-ups. While topical corticosteroids…
Read More
By Allison Sit A new American Academy of Dermatology (AAD) survey shows American adults may not fully understand the benefits of sunscreen. The survey of 1,000 adults found nearly one…
Read More
What Skin Toxicities May Signal in Melanoma Patients on Immunotherapy Cutaneous immune-related adverse events (irCAEs) are among the most common side effects seen in patients receiving immune checkpoint inhibitors (ICIs)…
Read More
Test Your Knowledge! Join Dr. Alexis Carrington, Chief Dermatology Resident at George Washington University, to help understand dermatologic conditions across all skin tones. Decoding Derm: What’s the Diagnosis is a…
Read More
Painless™ PDT vs. Conventional PDT: A Quick Look at Patient Comfort in AK Treatment Actinic keratosis (AK) is one of the most common conditions treated by dermatologists, and photodynamic therapy…
Read More
Melanoma Education on Instagram: What’s Missing—Especially for Skin of Color As melanoma rates rise, with a projected 7.3% increase in new cases and 3.8% rise in mortality in 2024, the…
Read More
What to Expect When Treating SCC In Situ with Mohs Surgery While squamous cell carcinoma in situ (SCCIS) is typically considered a low-risk skin cancer, treatment decisions, especially around surgical…
Read More
EMPSGC: Why Mohs Might Be the Better Choice Endocrine Mucin Producing Sweat Gland Carcinoma (EMPSGC) is rare, low-grade, and slow-growing—but it’s not without risk. Though uncommon, recurrence and even distant…
Read More
